Education
About Us
Working with TipRanks
Follow Us
Silexion Therapeutics (SLXN)
NASDAQ:SLXN
SLXN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.58 - $122.01
Previous CloseN/A
Volume52.80K
Average Volume (3M)640.47K
Market Cap
$6.27M
Enterprise Value$6.98M
Total Cash (Recent Filing)$1.19M
Total Debt (Recent Filing)$4.49M
Price to Earnings (P/E)―
Beta-0.25
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-19.98
Shares Outstanding8,692,392
10 Day Avg. Volume217,866
30 Day Avg. Volume640,468
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market Cap1.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.42
Forecast
1Y Price Target
$5.00Price Target Upside594.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Silexion Therapeutics News
PremiumCompany Announcements
Silexion Therapeutics Expands SIL204 Development Plan
---
Bulls Say, Bears Say
Bulls Say
Efficacy DataSIL-204 demonstrated highly positive results across different pancreatic cancer cell lines, validating the systemic administration strategy.
Market OpportunityTargeting metastatic pancreatic cancer significantly increases the market opportunity for SIL-204.
Strategic PartnershipsSilexion announced they have been partnered with Evonik, a leading German specialty chemicals company to develop SIL-204.
Bears Say
Financial OutlookThe additional dilution from the recent capital raise and warrant exercises has negatively impacted the stock's price target.
Stock ValuationThe 12-month price target has been lowered to $5.00, from $9.00 due to the additional dilution from the recent capital raise and warrant exercises.
---
Ownership Overview
―
Insiders
0.33% Mutual Funds
0.38% Other Institutional Investors
99.62% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
SLXN FAQ
What was Silexion Therapeutics’s price range in the past 12 months?
Silexion Therapeutics lowest stock price was $0.57 and its highest was $122.01 in the past 12 months.
What is Silexion Therapeutics’s market cap?
Silexion Therapeutics’s market cap is $6.27M.
When is Silexion Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Silexion Therapeutics’s earnings last quarter?
Silexion Therapeutics released its earnings results on Mar 18, 2025. The company reported -$0.77 earnings per share for the quarter, beating the consensus estimate of -$0.98 by $0.21.
Is Silexion Therapeutics overvalued?
According to Wall Street analysts Silexion Therapeutics’s price is currently Undervalued.
Does Silexion Therapeutics pay dividends?
Silexion Therapeutics does not currently pay dividends.
What is Silexion Therapeutics’s EPS estimate?
Silexion Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Silexion Therapeutics have?
Silexion Therapeutics has 8,692,392 shares outstanding.
What happened to Silexion Therapeutics’s price movement after its last earnings report?
Silexion Therapeutics reported an EPS of -$0.77 in its last earnings report, beating expectations of -$0.98. Following the earnings report the stock price went down -11.2%.
Which hedge fund is a major shareholder of Silexion Therapeutics?
Currently, no hedge funds are holding shares in SLXN
---
Company Description
Silexion Therapeutics
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
---
SLXN Stock 12 Month Forecast
Average Price Target
$5.00
▲(594.44% Upside)
Technical Analysis
Palatin Technologies
―
Soligenix
―
TransCode Therapeutics
―
Ocean Biomedical
―
Apollomics
―
Best Analysts Covering SLXN
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-63.42%
reiterated a buy rating 24 days ago
Copying Naz Rahman's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -63.42% per trade.
---